Full text is available at the source.
Abstract
The efficacy of once-weekly semaglutide in very old patients with type 2 diabetes, obesity, and heart failure is being analyzed.
- The study focuses on patients who are very old and have type 2 diabetes, obesity, and heart failure.
- Activities of daily living performance and health status are the main outcomes of interest.
- Glucagon-like peptide-1 receptor agonists have not been widely studied in this patient population.
Simplified